OMGA Omega Therapeutics Inc

Price (delayed)

$1.93

Market cap

$106.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$173.69M

Highlights
The company's gross profit has surged by 113% YoY and by 60% QoQ
The revenue has soared by 113% year-on-year and by 60% since the previous quarter
Omega Therapeutics's quick ratio has plunged by 67% YoY and by 16% from the previous quarter
The equity has dropped by 66% year-on-year and by 29% since the previous quarter

Key stats

What are the main financial stats of OMGA
Market
Shares outstanding
55.15M
Market cap
$106.45M
Enterprise value
$173.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.57
Price to sales (P/S)
21.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.17
Earnings
Revenue
$4.94M
EBIT
-$91.6M
EBITDA
-$84.32M
Free cash flow
-$77.96M
Per share
EPS
-$1.66
Free cash flow per share
-$1.41
Book value per share
$0.75
Revenue per share
$0.09
TBVPS
$3.33
Balance sheet
Total assets
$183.68M
Total liabilities
$142.33M
Debt
$127.62M
Equity
$41.35M
Working capital
$46.21M
Liquidity
Debt to equity
3.09
Current ratio
2.87
Quick ratio
2.49
Net debt/EBITDA
-0.8
Margins
EBITDA margin
-1,707.1%
Gross margin
100%
Net margin
-1,868.4%
Operating margin
-1,921.3%
Efficiency
Return on assets
-44.2%
Return on equity
-136%
Return on invested capital
-40.2%
Return on capital employed
-57.6%
Return on sales
-1,854.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OMGA stock price

How has the Omega Therapeutics stock price performed over time
Intraday
4.32%
1 week
-7.66%
1 month
-20.58%
1 year
-63.45%
YTD
-35.88%
QTD
-6.76%

Financial performance

How have Omega Therapeutics's revenue and profit performed over time
Revenue
$4.94M
Gross profit
$4.94M
Operating income
-$94.89M
Net income
-$92.28M
Gross margin
100%
Net margin
-1,868.4%
The company's gross profit has surged by 113% YoY and by 60% QoQ
The revenue has soared by 113% year-on-year and by 60% since the previous quarter
The net margin has surged by 60% year-on-year and by 41% since the previous quarter
The company's operating margin has surged by 59% YoY and by 41% QoQ

Growth

What is Omega Therapeutics's growth rate over time

Valuation

What is Omega Therapeutics stock price valuation
P/E
N/A
P/B
2.57
P/S
21.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.17
The EPS has grown by 25% YoY and by 8% from the previous quarter
The equity has dropped by 66% year-on-year and by 29% since the previous quarter
The stock's price to book (P/B) is 17% less than its last 4 quarters average of 3.1
The revenue has soared by 113% year-on-year and by 60% since the previous quarter
The price to sales (P/S) is 66% less than the last 4 quarters average of 63.4

Efficiency

How efficient is Omega Therapeutics business performance
The ROIC has soared by 68% YoY and by 24% from the previous quarter
OMGA's ROE has plunged by 64% YoY and by 23% from the previous quarter
The ROS has soared by 60% YoY and by 41% from the previous quarter
OMGA's return on assets is up by 32% year-on-year and by 8% since the previous quarter

Dividends

What is OMGA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OMGA.

Financial health

How did Omega Therapeutics financials performed over time
The total assets is 29% greater than the total liabilities
Omega Therapeutics's quick ratio has plunged by 67% YoY and by 16% from the previous quarter
Omega Therapeutics's current ratio has plunged by 65% YoY and by 14% from the previous quarter
The equity has dropped by 66% year-on-year and by 29% since the previous quarter
OMGA's debt to equity is up by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.